reports
- MarketLine Department
AdheraTherapeutics - Mergers & Acquisitions (M&A), Partnerships & Alli...
Summary Marketline's AdheraTherapeutics Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by AdheraTherapeutics since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic ...
- GlobalData Department
Mirna Therapeutics Inc (MIRN) - Pharmaceuticals & Healthcare - Deals a...
Summary Mirna Therapeutics Inc (Mirna) is a clinical stage biopharmaceutical company that develops and commercializes microRNA cancer therapeutics. The company through its microRNA replacement therapy technology develops products for cancer treatment. Its products MRX34, developed in such a way that it releases mimic of the naturally occurring microRNA tumor suppressor miR-34 that is under expressed due to cancer. MRX34 is in Phase I clinical trials and helps to treat multiple myeloma, malignan...
Mirna Therapeutics Announces Results of Annual Meeting of Stockholders
AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Mirna) (NASDAQ: MIRN) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held August 24, 2017, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganization, dated as of May 15, 2017, by and among Mirna, Meerkat Merger Sub, Inc. and Synlogic, Inc. (Synlogic), and the transactions contemplated thereby, including the me...
Synlogic and Mirna Therapeutics Agree to Merger
CAMBRIDGE, Mass. & AUSTIN, Texas--(BUSINESS WIRE)-- Privately held Synlogic, Inc., has entered into a definitive merger agreement with Mirna Therapeutics, Inc. (NASDAQ:MIRN) under which Synlogic will merge with a wholly owned subsidiary of Mirna in an all-stock transaction. The merged company will continue under the Synlogic name and will focus on advancing Synlogic’s drug discovery and development platform for Synthetic Biotic medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat ...
Mirna Therapeutics Reports First Quarter 2017 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided a corporate update. Following its late 2016 discontinuation of all research and development activities, the Company engaged a financial advisor and has been pursuing activities to evaluate strategic alternatives, including a possible merger or sale of the Company. Further operating cost and workforce reductions were also implemented to reduce overall ...
Mirna Therapeutics Reports Financial Results for the Fourth Quarter an...
AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2016 and provided a corporate update. Following its November 2016 decision to discontinue all research and development activities including the development of MRX34, Mirna began implementing operating cost reductions and organizational restructuring to reduce overall cash burn, including a reduction in its workforce. The Company engaged a fin...
Mirna Therapeutics Reports Third Quarter 2016 Financial Results and MR...
AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a biopharmaceutical company focused on microRNA-based oncology therapeutics, today reported financial results for the third quarter of 2016 and provided an update on recent developments. MRX34 CLINICAL PROGRAM In September 2016, the Company voluntarily halted the ongoing Phase 1 trial of its first product candidate, MRX34, following multiple immune-related serious adverse events (SAEs) observed in patients dosed with MRX34 over the cours...
Mirna Therapeutics Halts Phase 1 Clinical Study of MRX34
AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company, today announced its decision to close the ongoing Phase 1 study of MRX34, its investigational microRNA therapy for multiple cancers. The Company voluntarily halted enrollment and dosing in the clinical study following multiple immune-related severe adverse events (SAE) observed in patients dosed with MRX34 over the course of the trial. “Patient safety is the primary objective of our MRX34 Phase 1 clinical ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.